Schroder Investment Management Group Sells 260,199 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Schroder Investment Management Group trimmed its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 38.4% during the fourth quarter, Holdings Channel reports. The firm owned 417,253 shares of the company’s stock after selling 260,199 shares during the quarter. Schroder Investment Management Group’s holdings in Travere Therapeutics were worth $7,227,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Rhumbline Advisers increased its position in Travere Therapeutics by 2.2% during the fourth quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock worth $2,112,000 after buying an additional 2,640 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Travere Therapeutics by 13.5% during the 4th quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock worth $390,000 after acquiring an additional 2,666 shares during the period. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $53,000. Diversified Trust Co raised its stake in Travere Therapeutics by 27.5% in the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after acquiring an additional 3,169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Travere Therapeutics by 20.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company’s stock valued at $279,000 after purchasing an additional 3,458 shares during the last quarter.

Analyst Ratings Changes

Several research firms have commented on TVTX. JPMorgan Chase & Co. upped their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Scotiabank boosted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 12th. Citigroup upped their target price on Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Travere Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.46.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Peter Heerma sold 1,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total transaction of $30,000.96. Following the sale, the insider now directly owns 106,374 shares of the company’s stock, valued at $2,014,723.56. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Sandra Calvin sold 54,244 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. The trade was a 49.92 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 189,269 shares of company stock worth $4,155,251. 3.75% of the stock is currently owned by insiders.

Travere Therapeutics Price Performance

TVTX stock opened at $14.99 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -3.66 and a beta of 0.84. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a 50 day simple moving average of $20.48 and a 200 day simple moving average of $18.58. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.